To test the functional consequences of blocking the local renin-angiotensin system (RAS),
Introduction
In the renin-angiotensin system (RAS), the focus of research interest has recently shifted from an endocrine role to an autocrine/paracrine role as the key component of tissue/organand cell-specific functions; the latter was proposed almost 20 years ago as the concept of the local RAS (1) . Thus far, the local functions of RAS components, notably angiotensinogen and renin, have been reported in a variety of tissues (2) (3) (4) . These RAS components are regulated at a number of physiological steps that range from the synthesis of renin to the dimerization of angiotensin receptors. Accordingly, tissue concentrations of angiotensin II (Ang II), other RAS compo-nents and their active metabolites can be set independently of the circulatory RAS and may either potentiate systemic functions or have entirely separate activities to meet the specific needs of individual tissues (5) . Accumulating evidence indicates that impairments in the local RAS underlie certain tissue/organ disorders such as stroke and heart failure (3, 4, 6) . This gives rise to the possibility that a class of drugs that act on the local RAS may effectively ameliorate some of these disorders. In fact, a recent study has suggested similar consequences of the actions of such drugs on the local RAS (7) .
The early, remarkable success of angiotensin converting enzyme (ACE) inhibitors as a remedy for a plethora of diseases, including hypertension, arteriosclerosis, cardiac hypertrophy and diabetic renal disease, has encouraged the further development of drugs designed to inhibit the RAS and associated systems (8) . Among these drugs, the newest is an Ang II type 1 (AT1) receptor blocker (ARB), which has been specifically developed to better block the vasoconstricting, growthpromoting effects of Ang II directly at the receptor level. Therapeutic interventions involving ARBs as well as ACE inhibitors are considered to provide benefits at least in part through the interruption of the local RAS. With an enhanced understanding of the molecular biology of the local RAS, new avenues for therapeutic intervention will become possible.
Under these circumstances, we investigated the effects of the ARB candesartan on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissue) in the stroke-prone, spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat. We used DNA microarray technology to identify large clusters of genes that respond to the administration of candesartan in the context of the local RAS and hemodynamic impacts, such as blood pressure changes, on mRNA expression.
Methods

Animals
This study utilized a Japanese colony of male SHRSP and age-matched male WKY rats. Rats were weaned at 4 weeks after birth and placed on normal rat chow (SP diet, Funabashi Farm, Funabashi, Japan). A selected number of rats were treated with candesartan (5 mg/kg/d), dissolved in 0.15% polyethylene-glycol 300, 0.15% ethanol and 0.055% NaHCO3 for 4 weeks from 12 to 16 weeks of age. Also, to allow for the investigation of blood pressure-dependent mechanisms on systemic mRNA expression-i.e., whether a substantial part of mRNA expression changes are reproducible between different antihypertensive drugs with significant blood pressure decreases-rats were treated with hydralazine (10 mg/kg/d) independently of candesartan. Systolic blood pressure measurements were performed using the tail-cuff method, as previously described (9) . Briefly, three consecutive blood pressure readings were taken and an average was determined. The rats were killed under pentobarbital anesthesia (50 mg/kg, intraperitoneal infusion), which was immediately followed by the excision and snap freezing of organs at −70°C for subsequent RNA extraction. The intraperitoneal administration of pentobarbital was chosen because it was reported to have minimal effects on the expression of immediate-early genes (c-fos and c-jun) from 5 to 120 min after the induction of anesthesia in the brain, heart, liver and kidney of rats (10) .
All animals were treated in compliance with institutional regulations. The study protocol was approved by the animal ethics committee of the Research Institute, International Medical Center of Japan.
Drug Treatment
We first performed a pilot study to determine the dosage of candesartan using three different doses (1, 5, and 10 mg/kg/d) on 12-week-old male SHRSP (n= 2 each). Based on the results in this pilot study, we set an appropriate dose as 5 mg/ kg/d, because no further BP-lowering effects were attained above this level (data not shown). We then proceeded to the main study. Systolic blood pressure was measured by the tailcuff method every 3 to 4 d for 4 weeks. The vehicle of candesartan used in the present study was 0.15% polyethyleneglycol 300, 0.15% ethanol and 0.055% NaHCO3.
Similarly to the candesartan treatment, we determined an appropriate dose of hydralazine to be 10 mg/kg/d among three doses (1, 5, and 10 mg/kg/d) tested. The vehicle of hydralazine used in the present study was distilled water.
Tissue Processing and RNA Isolation
After harvest, whole organs of interest (brain, heart, kidney, liver and adipose tissue) were homogenized separately with a 0.5-inch-diameter generator shaft at a speed of 22,000 rpm for 60 s in a Polytron homogenizer PT1300D (Kinematica AG, Littau, Switzerland). Total RNA was extracted using RNeasy maxi kit (Qiagen, Valencia, USA) according to the manufacturer's protocol. The quality of RNA was checked with an RNA 6000 Nano LabChip on the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA) and then used in DNA microarray experiments. In the microarray analysis, four rats of the SHRSP and WKY strains were used in each treatment group of both candesartan and vehicle. Likewise, as for the treatment groups of hydralazine and vehicle in SHRSP, a microarray analysis was performed for the heart, in which, of the five organs, the most prominent mRNA expression changes were induced by candesartan. Total RNA extracted from each treatment group-that is, total RNA from two animals-was pooled, which led to the preparation of two samples (i.e., two pools derived from four animals) per each treatment group. The cDNA was synthesized from 1 μg of the DNase I-treated total RNA using the Omniscript RT (reverse transcriptase) Kit (Qiagen) and subjected to real-time PCR amplification.
Gene Expression Bioarrays
The present study utilized the CodeLink Bioarray Perfect system (GE Healthcare UK Ltd., Buckinghamshire, UK), which uses the UniSet Rat I Expression Bioarray that contains 9,028 gene probes, abbreviated hereafter as the 10K CodeLink array (11) (12) (13) (14) . The 10K CodeLink array accommodates a broad range of genes derived from publicly available, well-annotated mRNA sequences. This array is unique in that it is capable of detecting minimal differences in gene expression, i.e., as low as 1.3-fold with 95% confidence, because of its threedimensional aqueous gel matrix, on which empirically tested 30-mer oligonucleotides are deposited. This substantially reduces background noise, enhances sensitivity, and allows for the detection and quantification of subtle regulatory relationships among the genes tested.
All reagents were provided in the CodeLink Expression Assay Kit, except where noted. cRNA synthesis was performed according to the manufacturer's instructions using 2 μg of total RNA. The details of the target preparation, array hybridization, post-hybridization processing, and scanning were the same as described elsewhere (15) .
Microarray Data Analysis and Statistics
The CodeLink software package normalized the overall raw signal intensities on each array to their median value of all the rat probes. Normalized data were uploaded to GeneSpring GX (Agilent Technologies, Santa Clara, USA) for analysis. The threshold of detection was calculated using the normalized signal intensities for 300 negative controls on the array. Probes with signal intensity below this threshold were considered to be absent and were eliminated from the list. Since the low-intensity signals were most susceptible to noise, we filtered the data for spot quality by excluding all genes with a signal intensity smaller than 0.75 (compared with the median signal of 1.0) for each array. We assessed the differential expression of genes that passed these intensity filters by averaging the normalized signal intensities of two pools per group and calculating the ratio of the averaged values in the drugtreated group to those in the vehicle-treated group. Statistical significance was determined by Student's t-test (two-tailed, unpaired). Then, only genes that had p-values of < 0.05 were included in the analysis and further filtered for a level of 1.5-fold expression change. Gene ontology reports (Biological Process, Cellular Component, and Molecular Function, based on the Gene Ontology Consortium, http:// www.geneontology.org/GO.doc.html) (16) were sought through the GO Ontology Browser in GeneSpring GX. We also utilized GeneSpring GX's "Post Hoc Test" program, which enables users to identify genes as common (or unique) from multiple datasets of differentially expressed genes, to produce a list of genes that were up-or down-regulated in the current experimental setting. For readers' reference, we partially applied gross, functional categorization (17) to the ontology information on individual genes showing significant expression changes in the Results section.
Real-Time PCR Amplification
To validate the expression ratios of a subset of genes, we performed quantitative real-time PCR. The PCR primer sequences for target genes were originally designed ( Table 1) . The expression levels of seven rat genes were compared within four samples (i.e., two microarray pools) per group (drug vs. vehicle treatment group) using the 10K CodeLink arrays and within five samples per group using real-time PCR with standard curve methods. Real-time PCR amplifications were performed in a 384-well plate in the ABI 7900 HT Sequence Detection System (PE Applied Biosystems, Foster City, USA) in a total volume of 10 μL, which included 2 μL of template cDNA plus SYBR green I master mixture and a final concentration of 400 nmol/L each of forward and reverse primers. Each sample was analyzed in duplicate, and PCR amplification was performed as follows: 2 min at 50°C and 10 min at 95°C, followed by a total of 40 temperature cycles (15 s at 95°C and 1 min at 60°C). The numbers of copies of the PCR template in a starting sample were calculated by using the SEQUENCE DETECTOR system version 2.2.2, 
Results
Physiological Phenotypes
In 
Effects of Candesartan on Gene Expression in the Brain, Heart, Kidney, Liver and Adipose Tissues of SHRSP and WKY Rats
Using the 10K CodeLink array, the expression profiles of approximately 10,000 rat genes were analyzed in the brain, heart, kidney, liver and adipose tissues of SHRSP and WKY rats after 4 weeks of treatment with candesartan. The expression profiles were additionally analyzed in the hearts of SHRSP after 4 weeks of treatment with hydralazine to examine the potential impacts of blood pressure-dependent mechanisms on differential gene expression.
The present study was originally designed to extensively identify "signature" genes altered by candesartan treatment in individual organs of interest, irrespective of hypertension status, i.e., gene alteration commonly found in both SHRSP and WKY rats. However, we found only one gene in a single organ-namely, Ren1 in the kidney-to be differentially expressed in both SHRSP and WKY rats (Fig. 1 ). This finding is considered to corroborate the effectiveness of candesartan treatment in the present study.
The results of microarray analysis for candesartan treatment are shown separately for each rat strain (Tables 2 and 3 ).
Microarray Data in SHRSP (Table 2)
In the brain of SHRSP, only two genes, Ank2 and D123, were differentially expressed (down-regulated) between candesartan-and vehicle-treated animals. No genes were found to be up-regulated.
In the hearts of SHRSP, 69 genes were differentially expressed in the same experimental setting. Of these, 33 genes were up-regulated, and the functions of 20 genes (of the 33) are known to be involved in cellular metabolism, cell organization/biogenesis, regulation of cellular physiological process, transport, cell motility, and cell growth. The rest (36 genes) were down-regulated, of which 31 are known to be involved in cellular metabolism, transport, regulation of cellular physiological process, cell death, cell proliferation, cell motility, cell cycle, cell organization/biogenesis, cell homeostasis, and cell division.
In the kidneys of SHRSP, candesartan treatment up-regulated four genes, half of which (two genes) are known to play a role in the regulation of blood pressure. Ren1 is a rate-limiting enzyme of the RAS. Atp1a1 mediates Na + and K + transport to maintain water and electrolyte balance. Likewise, only three genes, Fos, Cd24 and Arc, were down-regulated. Fos is an immediate early gene encoding a nuclear protein involved in signal transduction, whereas Cd24 may be involved in neuronal migration during development. Arc is known to be involved in neuronal plasticity, long-term potentiation, and memory consolidation.
In the livers of SHRSP, candesartan treatment up-regulated two genes, Cckar and Slco1c1. Cckar is a G-protein-coupled receptor activated by cholecystokinin and may be involved in food intake and insulin regulation. Slco1c1 mediates the highaffinity transport of sulfated bile acids into hepatocytes.
In the adipose tissue of SHRSP, candesartan treatment upregulated 13 genes, 12 of which are known to be involved in transport, cell organization/biogenesis, cellular metabolism, cell motility, and extracellular matrix organization/biogenesis. Likewise, 19 genes were down-regulated, eight of which are known to be involved in cellular metabolism, transport, regulation of cellular physiological process, cell death, cell proliferation, cell motility, cell cycle, cell organization/biogenesis, cell homeostasis, and cell division.
Microarray Data in WKY Rats (Table 3)
In the brains of WKY rats, only one gene was differentially expressed (up-regulated) between candesartan-and vehicletreated animals. However, this gene is not well-characterized.
In the kidneys of WKY rats, two genes were differentially expressed. Of these two, Ren1 was up-regulated in a similar fashion as in the kidneys of SHRSP, and Calb1, which binds calcium, was down-regulated.
In the livers of WKY rats, three genes were differentially expressed, of which Zfp354a was up-regulated and is known to be a C2H2 class zinc finger-containing DNA-binding protein. Two genes were down-regulated, of which Tnfrsf12a is involved in cell proliferation, adhesion and angiogenesis.
In the heart and adipose tissue of WKY rats, no genes were significantly changed at the level of expression. 
Fig. 1. Scatter plots of gene expression changes induced by candesartan treatment in the five tested organs. The log2 expression ratio of [treatment/vehicle] is plotted against the results for SHRSP (x-axis) and WKY rats (y-axis) in each organ
Inter-Strain Differences in Gene Expression Changes Induced by Candesartan
When gene expression changes were compared between SHRSP and WKY rats, the most marked inter-strain difference was observed in the heart among the five tested organs ( Figs. 1 and 2 ). The overall baseline signal intensity of the microarray (i.e., at the vehicle-treated condition) tended to be higher in the hearts of SHRSP than in those of WKY rats, as indicated by the down-skewed scatter plots in Fig. 2B (upper scatter plots). To find the cause of the inter-strain difference in gene expression changes, we investigated the relationships between the comparative degree of gene expression in vehicle-treatment groups (which was represented by the log2-transformed ratio of baseline signal intensity in SHRSP to that in WKY rats) and the extent of expansion or reduction of inter-strain differences in gene expression (which was represented by inter-strain differences in log2-transformed fold 
Fig. 2. Scatter plots for inter-strain differences in gene expression changes induced by candesartan in the five tested organs. In the upper scatter plots, baseline signal intensity of microarray (i.e., at the vehicle-treated condition) is compared between SHRSP (x-axis) and WKY rats (y-axis) in each organ. The lower scatter plots depict relationships between the comparative size of gene expression in vehicle treatment groups (which was represented by the log2-transformed ratio of baseline signal intensity in SHRSP to that in WKY rats) (x-axis) and the extent of expansion or reduction of inter-strain differences in gene expression (which was represented by inter-strain differences in log2-transformed fold changes induced by candesartan treatment) (y-axis).
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Ave. signal intensity in WKY Ave. signal intensity in SHRSP changes induced by candesartan treatment) ( Fig. 2A-E , lower scatter plots). There appeared to be an inverse correlation between these two parameters, suggesting that candesartan treatment reduced the "preexisting" inter-strain difference in gene expression. That is, the larger the inter-strain difference was for a given gene expression in the vehicle-treated group, the more prominent was the gene expression change induced by candesartan treatment in the hearts of SHRSP. Physiolog- Significantly changed in hydralazine Tx ically, candesartan could have caused the marked inter-strain difference in the reduction of blood pressure and also could have significantly alleviated the cardiac hypertrophy in SHRSP. Thus, it is plausible that the observed inter-strain difference in gene expression profile that was ameliorated by candesartan treatment can be ascribed mainly to blood pressure-dependent mechanisms. Similarly to the heart, the interstrain difference was noticeable in the kidney and adipose tissue but not necessarily in the brain and liver (Fig. 1) .
Fig. 3. Scatter plots depicting log2-transformed ratios of SHRSP and WKY rats for candesartan treatment (y-axis) against those for vehicle treatment (x-axis) according to the patterns of individual gene expression changes by candesartan and hydralazine. Genes (probes) tested in microarray analysis are categorized into four plots (from upper left to lower right in the figure) as follows: genes without significant changes by either of drugs (n= 6,314), genes with significant changes by hydralazine (n= 754), genes with significant changes by candesartan (n= 224), and genes with significant changes by both drugs (n= 26
Comparison of Gene Expression Changes in the SHRSP Heart between Candesartan and Hydralazine Treatments
Although not completely equivalent to candesartan, hydralazine (10 mg/kg/d) was found to significantly lower systolic blood pressure in SHRSP. For hydralazine treatment, we performed microarray analysis in the heart, in which the most marked inter-strain difference was observed for candesartan treatment, to examine whether this inter-strain difference could be substantially ascribed to blood pressure-dependent mechanisms.
A total of 7,318 genes (probes) passed our microarray data filtering for spot quality. Among them, only 26 genes (0.35%) showed significant (p< 0.05 by unpaired t-test, and < 0.67 or ≥ 1.5 fold) expression changes induced by both drugs in common, while 224 (3.1%) and 754 (10.3%) genes showed significant changes in expression by candesartan and hydralazine, respectively, at the relevant statistical thresholds (Fig. 3) . In line with Fig. 2 , we further evaluated the extent of expansion or reduction of inter-strain differences in gene expression by plotting the log2 ratios of SHRSP and WKY rats for candesartan treatment (in the y-axis) against those for vehicle treatment (in the x-axis) according to the patterns of individual gene expression changes from the two drugs. Here, in each plot, the regression lines would make a smaller angle with the x-axis, as inter-strain differences in gene expression could have been reduced by candesartan treatment. The slopes of the regression lines appeared to near the x-axis (from 0.63 to 0.41) in the following order: genes without significant changes by either of drugs, genes with significant changes by hydralazine, genes with significant changes by candesartan, and genes with significant changes by both drugs (Fig. 3) . Gene expression changes in the hearts of SHRSP were found to be more prominent for hydralazine than for candesartan treatment as a whole, and there was a relatively weak but significant correlation between the two drug treatments (correlation coefficient = 0.083, p< 0.0001, r 2 = 0.007). Thus, both hemodynamic and drug-specific factors cooperatively contributed to the overall tendency of reduction in inter-strain differences in gene expression induced by candesartan.
Validation of DNA Microarray Data by Real-Time PCR Amplification
We validated the accuracy of the differential expression ratios from the 10K CodeLink array by comparing them with the data obtained using quantitative RT-PCR (TaqMan ® assay; PE Applied Biosystems, Foster City, USA) for a subset of seven genes (Table 4) . While only two pools (two samples per microarray pool, i.e., n= 4 in total) were compared between candesartan and vehicle treatment groups in the present study, the 10K CodeLink turned out to generate expression ratios that were in good agreement with those of TaqMan ® .
Discussion
The present study, for the first time, provides comprehensive profiles of gene expression induced by candesartan treatment in five organs of the hypertensive rat strain SHRSP, where the local RAS is supposed to have important cardiovascular function. Candesartan differentially modulated gene expression profiles in the brain, heart, kidney, liver and adipose tissues of SHRSP in an organ-specific manner. Of the five organs tested, gene expression was most prominently altered in the hearts of SHRSP. In contrast, candesartan treatment exerted minimal or no significant effects on gene expression profiles in the corresponding organs of normotensive WKY rats. These inter-strain differences in gene expression changes induced by candesartan seemed to be associated with both blood pressure-dependent and independent mechanisms. The present study is the first to provide a global profile of cardiac gene expression as modulated by ARB in a genetic model of hypertension. The RAS components are locally expressed in the heart and capable of generating Ang II. It is known that the cardiac RAS is involved in the induction of hypertrophy, fibrosis and remodeling and is therefore of significant clinical relevance to the study of hypertension and heart failure (4) (5) (6) 18) . Our observation that candesartan induces a prominent alteration in cardiac gene expression strengthens the general understanding that locally generated angiotensin peptides have multiple and novel diverse actions, including cell growth, cell proliferation and cell death (5) . Along this line, notably, some experimental and clinical studies have demonstrated that AT1 receptor antagonists can attenuate most of the deleterious effects of Ang II in the heart (19) . The cardiac genes altered in SHRSP in the present study are involved in cellular events including metabolism, regulation of physiological process, ion transport, organization and biogenesis, motility, death, proliferation, cycle and growth, and homeostasis, which partly overlap with the genes previously reported (20) (21) (22) but also include novel genes, e.g., thrombospondin 4 (Thbs4), latent transforming growth factor β binding protein 2 (Ltbp2) and tenascin C (Tnc) ( Table 4 ).
These observations provide a basis on which we can dissect the complex cardioprotective mechanisms that underlie the local cardiac RAS and its interaction with other systems.
The local RAS is also assumed to play a role in the brain and has been implicated in the pathogenesis and outcome of stroke (3, 7) . Ang II exerts most of its well-defined physiologic actions through the stimulation of an AT1 receptor subtype. This receptor subtype not only may contribute to strokerelated pathologic mechanisms (e.g., hypertension and atherothrombosis) but also may be involved in post-ischemic damage to the brain (23) . Animal studies to date have shown that only the effective blockade of brain AT1-receptors exerts neuroprotective effects in ischemic neuronal tissues and consequently improves the neurological outcome of focal brain ischemia (23) . In this context, it is reported that candesartan is the most effective ARB to cross the blood-brain barrier and the current dosage seems to be sufficient to block AT1-receptors in the brain according to the dosage (0.1-3 mg/kg/d) used in the previous studies (23) (24) (25) . The SHRSP animal model tested in this study is known to exhibit a propensity for stroke and seems to be appropriate for physiological investigation of neuroprotective effects of candesartan treatment. Surprisingly, we could find much less modest changes in gene expression in the brains of SHRSP than in the hearts of SHRSP. In fact, only two genes involved in the cell cycle and signal transduction process turned out to be significantly modulated (down-regulated) by candesartan treatment in the current experimental setting. Zhou et al. (24) also performed microarray analysis on brain microvessels after 4 weeks of candesartan administration (0.3 mg/kg/d) via a subcutaneously implanted osmotic mini-pump. This study reported that a larger number of probes (genes) were significantly altered at the level of mRNA expression by candesartan treatment in WKY rats than in the spontaneously hypertensive rat (SHR), while a total of 16 probes including stress-related genes such as stathmin were down-regulated to the same extent in both strains. Accordingly, the authors argued that candesartan could target many genes in brain microvessels through blood pressure-independent mechanisms. This appears to be in accordance with our observations of the brain; that is, that fold changes of gene expression tended to be larger in WKY rats than in SHRSP (Fig. 1) , although differentially expressed genes were equivalent in number at the arbitrarily defined cutoff levels in Table 2 (p< 0.05 by unpaired t-test, and < 0.5 or ≥ 2.0 fold).
All components of the RAS are found in the kidney, with each being compartmentalized in the organ's tubular and interstitial networks. Above all, it should be noted that the Ren1 gene was most prominently (> 10 fold) up-regulated by candesartan treatment in the kidneys of both rat strains, which indicated a successful blockade of the local RAS in the current experimental setting. As considerable amounts of Ang II are formed locally, it is debated that intra-renally formed Ang II is more important than circulating Ang II in controlling renal function. However, we could find much subtler gene expression changes in the kidneys than in the hearts of SHRSP. Likewise, we found a limited number of genes to be significantly altered in the livers of SHRSP.
Of particular note in this study is the fact that, next to the heart, the adipose tissue had the second most significant alterations in gene expression induced by candesartan. The SHRSP is generally known to be a model of insulin resistance in humans and is characterized by reduced insulin-mediated glucose disposal and defective fatty acid metabolism in the isolated adipocytes (26) . Accumulating evidence has been provided for the existence of the local RAS in human adipose tissues, which may function independently of circulating RAS and has been implicated in the pathogenesis of metabolic syndrome (27) . Importantly, enhanced Ang II signaling and the subsequent metabolic disturbances in the adipose tissue are considered potential therapeutic targets for the prevention of cardiovascular complications in metabolic syndrome (28) . Along this line, the present data may help clarify the mechanisms linking the adipose tissue RAS to the development of insulin resistance in hypertension and metabolic syndrome.
Recently, it has been shown that hypertension-related endorgan damage largely depends on the level of blood pressure (29) , but some people have argued that it is also substantially influenced by the activation of the local RAS (30) . Generally, it is difficult to separate blood pressure-dependent mechanisms from blood pressure-independent mechanisms when we evaluate pharmacological impacts of a particular antihypertensive drug on end-organ damage. It would be valuable to compare the results for a hypertensive rat strain (SHRSP in this study) with those for a normotensive rat strain (WKY rats in this study) (Fig. 1) ; the extent of blood pressure reduction by antihypertensive treatment significantly differed between these strains, implying that differential gene expression unique to SHRSP is substantially explained by blood pressure-dependent mechanisms. To verify this speculation, we compared treatment with candesartan and hydralazine with respect to gene expression changes in the heart of SHRSP and found that both hemodynamic (i.e., blood pressure-dependent) and drug-specific (i.e., blood pressure-independent) factors could cooperatively contribute to the overall tendency of reduction of inter-strain differences in gene expression induced by candesartan. This also seems to be applicable for the results of gene expression in the kidneys of SHRSP. The lack of apparent inter-strain differences in the brains of SHRSP, on the other hand, needs to be carefully interpreted, which may simply indicate the relatively mild gene expression changes in the brain because of the drug's organ specificity observable in the current experimental setting. Of particular note is the fact that differential gene expression was prominent in the adipose tissue of SHRSP after candesartan treatment. The underlying mechanism remains to be elucidated, but one possible explanation is that the "enhanced" RAS in the adipose tissue may be calmed down by the pharmacological property of candesartan, whether it is the primary cause of hypertension or the phenomenon secondary to increased blood pressure (31) . When the reference of pharmacological property was set to WKY rats, candesartan treatment appeared to reduce the "pre-existing" inter-strain difference in gene expression in most of the organs tested (Fig. 2) . In this context, it must be noted that candesartan treatment induces only a modest degree of gene expression changes at the current dose in the normotensive WKY rats (Table 3) . Thus, candesartan treatment is considered to ameliorate-in an organ-specific manner and by acting principally on the local RAS-gene expression changes through both blood pressure-dependent and -independent mechanisms at a variety of pathophysiological stages in vivo.
While a number of genes altered by candesartan in SHRSP have been characterized, detailed functions of many genes remain unknown. The list of genes thus detected in the present study can provide insights into the beneficial effects of ARB, such as candesartan, on the cardiovascular system. Moreover, differential organ-or tissue-specific gene expression changes caused by candesartan may help delineate the mechanisms that underlie the organ or tissue protection conferred by ARB at the levels of cellular biology and genetics, and these findings will contribute to pharmacogenetics. Further studies are warranted to investigate not only the individual genes of interest but also the genetic "networks" that involve differential organ-or tissue-specific gene expression induced by the blockade of RAS in essential hypertension.
